On February 16, 2022 Mydecine Innovations Group (MYCO.NEO) announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in their family of psilocin analogs. Founded in…
MYCO.NE
Jody speaks with Josh Bartch, CEO and director of Mydecine Innovations Group (MYCO.NEO), a psychedelics company focused on advancing its lead psilocybin drug candidate MYCO-001 into Phase II clinical…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
The psychedelics sector is looking ready for a reversal. We are just waiting for the breakout confirmation. Earlier this week, we discussed how the bottom is in for cannabis…
Mydecine Innovations Group (MYCO.NEO) inked a letter of intent (LOI) with Alberta-based inter-disciplinary mental health clinic operator, The Newly Institute, to collaborate on getting psychedelic assisted therapy to patients….
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…
Mydecine Innovations (MYCO.NE) announced they are filing a new patent for their MDMA-like compounds. In the press release Mydecine writes that “this expansive patent would allow Mydecine to scale…